{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:55:37Z","timestamp":1792104937088,"version":"4.4.0"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Summit Therapeutics, LLC","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2023,10,18]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We have previously reported on the susceptibility and epidemiology of\n            <jats:italic>Clostridioides difficile<\/jats:italic>\n            isolates from six geographically dispersed medical centers in the United States. This current survey was conducted with isolates collected in 2020\u20132021 from six geographically dispersed medical centers in the United States, with specific attention to susceptibility to ridinilazole as well as nine comparators.\n            <jats:italic>C. difficile<\/jats:italic>\n            isolates or stools from patients with\n            <jats:italic>C. difficile<\/jats:italic>\n            antibiotic-associated diarrhea were collected and referred to a central laboratory. After species confirmation of 300 isolates at the central laboratory, antibiotic susceptibilities were determined by the agar dilution method [M11-A9, Clinical and Laboratory Standards Institute (CLSI)] against the 10 agents. Ribotyping was performed by PCR capillary gel electrophoresis on all isolates. Ridinilazole had a minimum inhibitory concentration (MIC) 90 of 0.25 mcg\/mL, and no isolate had an MIC greater than 0.5 mcg\/mL. In comparison, fidaxomicin had an MIC 90 of 0.5 mcg\/mL. The vancomycin MIC 90 was 2 mcg\/mL with a 0.7% resistance rate [both CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria]. The metronidazole MIC 90 was 1 mcg\/mL, with none resistant by CLSI criteria, and a 0.3% resistance rate by EUCAST criteria. Among the 50 different ribotypes isolated in the survey, the most common ribotype was 014\u2013020 (14.0%) followed by 106 (10.3%), 027 (10%), 002 (8%), and 078\u2013126 (4.3%). Ridinilazole maintained activity against all ribotypes and all strains resistant to any other agent tested. Ridinilazole showed excellent\n            <jats:italic>in vitro<\/jats:italic>\n            activity against\n            <jats:italic>C. difficile<\/jats:italic>\n            isolates collected between 2020 and 2021 in the United States, independent of ribotype.\n          <\/jats:p>","DOI":"10.1128\/aac.00349-23","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T13:00:31Z","timestamp":1695214831000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":15,"title":["A US-based national surveillance study for the susceptibility and epidemiology of\n            <i>Clostridioides difficile<\/i>\n            isolates with special reference to ridinilazole: 2020\u20132021"],"prefix":"10.1128","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0119-3978","authenticated-orcid":false,"given":"D. R.","family":"Snydman","sequence":"first","affiliation":[{"name":"Tufts Medical Center , Boston, Massachusetts, USA"},{"name":"Tufts University School of Medicine and the Stuart B. Levy Center for the Integrated Management of Antimicrobial Resistance , Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6014-9761","authenticated-orcid":false,"given":"L. A.","family":"McDermott","sequence":"additional","affiliation":[{"name":"Tufts Medical Center , Boston, Massachusetts, USA"},{"name":"Tufts University School of Medicine and the Stuart B. Levy Center for the Integrated Management of Antimicrobial Resistance , Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Thorpe","sequence":"additional","affiliation":[{"name":"Tufts Medical Center , Boston, Massachusetts, USA"},{"name":"Tufts University School of Medicine and the Stuart B. Levy Center for the Integrated Management of Antimicrobial Resistance , Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J. C.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Kindred Health Care System , Rancho Cucamonga, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. N.","family":"Schuetz","sequence":"additional","affiliation":[{"name":"Mayo Clinic School of Medicine and Science , Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Edward Hines, Jr. VA Hospital , Hines, Illinois, USA"},{"name":"Loyola University Medical Center , Maywood, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. N.","family":"Gerding","sequence":"additional","affiliation":[{"name":"Edward Hines, Jr. VA Hospital , Hines, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gluck","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine , Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bourdas","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine , Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. C.","family":"Carroll","sequence":"additional","affiliation":[{"name":"University of Houston College of Pharmacy , Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. K.","family":"Lancaster","sequence":"additional","affiliation":[{"name":"Summit (Oxford) Ltd , Abingdon, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. W.","family":"Garey","sequence":"additional","affiliation":[{"name":"Summit (Oxford) Ltd , Abingdon, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Wang","sequence":"additional","affiliation":[{"name":"Montana State University , Bozeman, Montana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. T.","family":"Walk","sequence":"additional","affiliation":[{"name":"Montana State University , Bozeman, Montana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Duperchy","sequence":"additional","affiliation":[{"name":"Johns Hopkins Hospital , Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.5009\/gnl.2014.8.1.1"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176797"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1505190"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532"},{"key":"e_1_3_2_6_2","volume-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control and Prevention","year":"2013","unstructured":"Centers for Disease Control and Prevention . 2013. Antibiotic resistance threats in the United States. US Department of Health and Human Services, Washington, DC."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.050978"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01136-13"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30235-9"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199810"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00046.2020"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis338"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1372"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00845-15"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00391-19"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03772-z"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/671728"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anaerobe.2020.102185"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab718"},{"key":"e_1_3_2_20_2","volume-title":"Abstract presented at ID weekRi-codify phase 3, randomized, double blind study to evaluate the efficacy and safety of ridinilazole compared to vancomycin for the treatment of Clostridioides difficile infection","author":"Okhuysen PC","year":"2022","unstructured":"Okhuysen PC , Ramesh M , Garey KW , Louie TJ , Cisneros JT , Stychneuskaya A , Kiknadze N , Li J , Duperchy E , Wilcox PMH , Montoya JG , Styles L , Clow F , James D , Dubberke ER , De Oliveira CM , Van Steenkiste C . 2022. Abstract presented at ID week. Ri-codify phase 3, randomized, double blind study to evaluate the efficacy and safety of ridinilazole compared to vancomycin for the treatment of Clostridioides difficile infection. Washington, DC."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00446-19"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2709.203468"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2016.12.001"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910215"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.9.2.214-219.1979"},{"key":"e_1_3_2_26_2","volume-title":"Wadsworth-KTL anaerobic Bacteriology manual","author":"Jousimies-Somer HR","year":"2002","unstructured":"Jousimies-Somer HR , Summanen P , Citron DM , Baron EJ , Wexler HA , Finegold SM . 2002. Wadsworth-KTL anaerobic Bacteriology manual. 6th ed. Star Publishing Company, Belmont, CA.","edition":"6"},{"key":"e_1_3_2_27_2","volume-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute . 2018. CLSI publication number M11-A9, In Methods for antimicrobial susceptibility testing of anaerobic bacteria. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_28_2","volume-title":"Performance standard for antimicrobial susceptibility testing31st Informational Supplement","author":"Clinical and Laboratory Standards Institute","year":"2021","unstructured":"Clinical and Laboratory Standards Institute . 2021. CLSI document M100-S31, In Performance standard for antimicrobial susceptibility testing. 31st Informational Supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_29_2","volume-title":"Pfizer product monograph","author":"Tygacill","year":"2017","unstructured":"Tygacill . 2017. Pfizer product monograph. Pfizer, Kirkland, Canada. https:\/\/www.pfizer.ca\/sites\/default\/files\/201710\/TYGACIL_PM.pdf."},{"key":"e_1_3_2_30_2","first-page":"0","volume-title":"VersionBreakpoint tables for interpretation of Mics and zone diameters","author":"The European Committee on Antimicrobial Susceptibility Testing","year":"2021","unstructured":"The European Committee on Antimicrobial Susceptibility Testing . 2021. Version. Breakpoint tables for interpretation of Mics and zone diameters, Vol. 11, p 0."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03591-14"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00349-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00349-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T13:03:59Z","timestamp":1697634239000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00349-23"}},"subtitle":[],"editor":[{"given":"Jared A.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,18]]}},"alternative-id":["10.1128\/aac.00349-23"],"URL":"https:\/\/doi.org\/10.1128\/aac.00349-23","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"assertion":[{"value":"2023-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00349-23"}}